Cyclosporine for the treatment of HLTV-1-induced HAM/TSP: An experience from a case report

Adrián Sánchez-Montalvá, Fernando Salvador, Estrella Caballero, Israel Molina

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

© 2015 Wolters Kluwer Health, Inc. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains a challenging disease. Treatment options are scarce, and their safety and efficacy are currently a matter of concern.We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who started with a gait disturbance at Vall d'Hebron University Hospital (Barcelona) from August 2012 to October 2013. After 62 weeks of treatment, clinical improvement was observed and proviral load diminished. No safety concerns were observed.Cyclosporine seems to be effective in new-onset HAM/TSP or in chronic HAM/TSP that develops a relapse. However, the duration and safety profile of this steroid-sparing therapy remain unknown and should be further investigated.
Original languageEnglish
Pages (from-to)e382
JournalMedicine (United States)
Volume94
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Fingerprint Dive into the research topics of 'Cyclosporine for the treatment of HLTV-1-induced HAM/TSP: An experience from a case report'. Together they form a unique fingerprint.

Cite this